Melbourne, April 23, 2009 (ABN Newswire) - Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that it had received notification from GlaxoSmithKline (LON:GSK) that Relenza sales were A$462 million and indicative royalties were A$32.3 million, for the three months ended 31 March 2009.

Indicative royalties for the nine months to 31 March 2009 total A$36.1 million.

Biota CEO Peter Cook attributed the performance to recent significant orders for pandemic stockpiling from the UK and Japanese Governments.

Contact

Investor / Analyst Enquiries
Biota Holdings Limited
Peter Cook
Tel: +61-3-9915-3720

Damian Lismore
Tel: +61-3-9915-3721



Related Companies

GlaxoSmithKline plc       
Biota Holdings Limited        


ABN Newswire This Page Viewed:  (Last 7 Days: 15) (Last 30 Days: 62) (Since Published: 6873)